Monday, August 13, 2012
Quintiles, a fully integrated biopharmaceutical services company, has acquired Expression Analysis (EA), a Durham, N.C.-based provider of genomics testing and analysis to biopharma, academic, government and non-profit customers. Terms of the transaction were not disclosed.
Expression Analysis is the latest in a series of Quintiles acquisitions and alliances designed to help the latter’s customers leverage the power of genomics to better understand diseases; develop diagnostic tools; and deliver safer, more effective therapies based on the genetic makeup of the disease and the patient.
“The addition of EA’s ‘Genomic Know-How’ to Quintiles is another step forward in our efforts to bring personalized medicine into mainstream drug development,” said Thomas Wollman, senior vice president of global laboratories, Quintiles. “Its expertise in genetic sequencing and advanced bioinformatics is essential to understanding diseases and drugs at the molecular level. That’s a huge step in creating more value across the healthcare spectrum.”
Steve McPhail, president and CEO of EA, said, “The combination of Quintiles’ global laboratories and EA genomic technology excellence will facilitate worldwide access to resources and expertise to drive improvements in the diagnosis, treatment and management of complex disease. EA can now play a global role in helping biopharma succeed in the New Health.”
EA provides whole genome to focused-set gene expression and genotyping assays, along with next-generation sequencing services, sequence enrichment technologies and bioinformatics support. It offers a broad range of services across multiple platforms. Its system follows CLSI guidelines and its CLIA-registered laboratory supports GLP compliance.